The big pharmaceutical companies are increasingly withdrawing from the fight against multidrug-resistant bacteria. Biotech companies have taken a step to replace them but they may not have enough experience of developing new drugs to provide the next generation of antiinfectives.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Related links
Related links
Related links in Nature Research
https://doi.org/10.1038/Nat.Biotechnol.,21,1255-1256(2003)
https://doi.org/10.1038/Nat.Biotechnol.,17,1165-1169(1999)
Related external links
Rights and permissions
About this article
Cite this article
Sheridan, C. Antiinfective biotechs face partnering gap. Nat Biotechnol 23, 155–156 (2005). https://doi.org/10.1038/nbt0205-155
Issue Date:
DOI: https://doi.org/10.1038/nbt0205-155
This article is cited by
-
The porin and the permeating antibiotic: a selective diffusion barrier in Gram-negative bacteria
Nature Reviews Microbiology (2008)
-
Future trends and challenges in pathogenomics
EMBO reports (2005)